Sign In  |  Register  |  About San Anselmo  |  Contact Us

San Anselmo, CA
September 01, 2020 1:33pm
7-Day Forecast | Traffic

  • Search Hotels in San Anselmo

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Arbutus Biopharma Corp (NQ: ABUS )

3.460 +0.020 (+0.58%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Arbutus Biopharma Corp

< Previous 1 2 3 4 Next >
Walmart To Rally More Than 15%? Here Are 10 Top Analyst Forecasts For Wednesday
Via Benzinga
Alnylam's Concedes Its Patent Infringement Case Against Moderna's COVID-19 Vaccine
Alnylam Pharmaceuticals has conceded that Moderna's products do not infringe on its patents, as a court ruling determined. Both companies have agreed to dismiss the case without prejudice for possible... 
Via Benzinga
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
Arbutus Layoffs 2024: What to Know About the Latest ABUS Job Cuts
While the Arbutus layoffs represents a major overhaul operationally, the market has responded positively to ABUS stock. Here’s why. 
Via InvestorPlace
Topics Workforce
Exposures Layoff
ABUS Stock Earnings: Arbutus Biopharma Beats EPS, Misses Revenue for Q1 2024
ABUS stock results show that Arbutus Biopharma beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024. 
Via InvestorPlace
3 Healthcare Stocks Short Sellers Are Prescribing for Trouble
The healthcare industry is one of the most potent yet also one of the most competitive. This has short sellers out for blood. 
Via InvestorPlace
Earnings Scheduled For February 29, 2024
Companies Reporting Before The Bell • Frontline (NYSE:FRO) is expected to report quarterly earnings at $0.46 per share on revenue of $276.19 million. 
Via Benzinga
Arbutus Biopharma Q1 Exceeds Consensus View; Cuts Cash Burn Guidance
Via Benzinga
Recap: Arbutus Biopharma Q1 Earnings
Via Benzinga
Arbutus Biopharma's Earnings Outlook
Via Benzinga
Arbutus Vs. Moderna Patent Dispute Over Covid-19 Vaccine Gets Response From Judge
Delaware Judge favors Arbutus and Genevant Sciences in their patent dispute with Moderna over COVID-19 vaccine technology. 
Via Benzinga
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
Moderna Shares Slip Over Covid Vaccine Patent Dispute, But Chart Signals Potential Rebound Ahead
Moderna stock falls 2.32% due to patent infringement suit. However, some investors see this as an opportunity to enter or average out. Golden Cross formation also offers hope for future growth. 
Via Benzinga
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
Arbutus Stock Soars 20% As It Heads To Trial With Moderna In Covid Vaccine Patent Claim
Arbutus Biopharma soared more than 20% on Wednesday, April 3, after the company received permission to pursue a claim against Moderna in court. 
Via Benzinga
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
Small Biotech Promosome Drops Lawsuit Against Pfizer, BioNTech in COVID-19 Vaccine Patent Dispute
Biotech firm Promosome has agreed to end the lawsuit, which accused the COVID-19 vaccine manufacturers, Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX), of patent infrin 
Via Benzinga
Topics Intellectual Property Lawsuit
Exposures COVID-19 Financial Intellectual Property
Why Arbutus Biopharma Stock Is Sinking Today
After a strong start to 2023, the virology-focused biopharma company has hit a regulatory speed bump. 
Via The Motley Fool
Why Arbutus Biopharma Stock Is Plunging Today
Via Benzinga
Arbutus Biopharma's Return On Capital Employed Insights
Via Benzinga
Recap: Arbutus Biopharma Q2 Earnings
  Arbutus Biopharma (NASDAQ:ABUS) reported its Q2 earnings results on Thursday, August 4, 2022 at 07:30 AM. Here's what investors need to know about the announcement. 
Via Benzinga
US Court Favors Moderna In COVID-19 Vaccine Patent Infringement Case With Arbutus Biopharma
Via Benzinga
Pfizer Slapped With Additional Patent Infringement Lawsuit Over Its Famed COVID-19 Shots
Via Benzinga
Pfizer, BioNTech Fire Back At Moderna Over COVID-19 Vaccine Related Patent Claims
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Investors can start off the day with a breakdown of the biggest pre-market stock movers for Tuesday and the news moving those shares! 
Via InvestorPlace
Arbutus Biopharma: Q1 Earnings Insights
Arbutus Biopharma (NASDAQ:ABUS) reported its Q1 earnings results on Thursday, May 5, 2022 at 07:30 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Moderna Entangles Pfizer/BioNTech In COVID-19 Vaccine Patent Lawsuits: All You Need To Know
Moderna Inc (NASDAQ: MRNA) has  
Via Benzinga
Biotech Daily: Amgen, Gilead Go Shopping, Nod For AstraZeneca's Lynparza In Early Stage Breast Cancer, Decision Day For Alzheimer's Associated Hallucinations Candidate
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Daily Biotech Pulse: Liver Disease-Focused Gene Therapy Pact, Assembly Bio Stops HBV Infection Trial, X4 Pharma Looks For Partners
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Pfizer Dives As CureVac Tees Up A Patent Suit Aimed At Its BioNTech-Partnered Covid Shot
The company isn't seeking an injunction, but wants "fair compensation." 
Via Investor's Business Daily
Pfizer Dives As CureVac Tees Up A Patent Suit Aimed At Its BioNTech-Partnered Covid Shot
The company isn't seeking an injunction, but wants "fair compensation." 
Via Investor's Business Daily
This Analyst Says Arbutus' EASL Presentations Outline Path For A Functional Cure For Chronic Hepatitis B
Via Benzinga
Morning Brief: Top Financial Stories Dominating on Monday, May 9
CNBC Ford Motor Selling 8M Shares Of Rivian Automotive 
Via Benzinga
Moderna Files Motion To Dismiss COVID-19 Vaccine Related Patent Claims: WSJ
Moderna Inc (NASDAQ: MRNA) is trying to fight off rival companies’ patent infringement claims related to its COVID-19 vaccine, arguing that the companies may only pursue their claims by seeking... 
Via Benzinga
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 SanAnselmo.com & California Media Partners, LLC. All rights reserved.